CD8A and neoplasm: Initial studies evaluating combination OV and checkpoint blockade therapy in mice generated data that underscores the notion that the therapeutic efficacy of oncolytic virotherapy is primarily contrived from the tumor-specific immune response coordinated by NK cells and carried out by CD8+ T cells, rather than direct virus-mediated lysis.